Replay's cell therapy product company Syena announces first patient dosed in Phase 1/2 study of TCR-NK cell therapy for multiple myeloma

Replay’s cell therapy product company Syena announces first patient dosed in Phase 1/2 study of TCR-NK cell therapy for multiple myelomaPhase 1/2 ...

Related Keywords

New York ,United States ,London ,City Of ,United Kingdom ,California ,San Diego ,Houston ,Texas ,Katy Rezvani ,Adrian Woolfson Lachlan Mackinnon ,Lachlan Mackinnon ,Adrian Woolfson ,University Of Texas Md Anderson Cancer Center ,Melinda Gates Foundation ,Twitter ,Linkedin ,Professor Katy Rezvani ,T Cell Receptor Natural Killer ,Cancer Center ,Stem Cell Transplantation ,Cellular Therapy ,Executive Chairman ,Lansdowne Partners ,Melinda Gates ,Natural Killer ,New York Esophageal Squamous ,